risedronic acid has been researched along with Hyperparathyroidism, Primary in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Hyperparathyroidism, Primary: A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tournis, S | 1 |
| Fakidari, E | 1 |
| Dontas, I | 1 |
| Liakou, C | 1 |
| Antoniou, J | 1 |
| Galanos, A | 1 |
| Marketou, H | 1 |
| Makris, K | 1 |
| Katsalira, K | 1 |
| Trovas, G | 1 |
| Lyritis, GP | 1 |
| Papaioannou, N | 1 |
1 other study available for risedronic acid and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Hyperparathyroidism, | 2014 |